Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Tonix Pharmaceuticals Holding (TNXP) Other Gross PP&E Adjustments (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Other Gross PP&E Adjustments over the past 3 years, most recently at $37.4 million for Q4 2025.

  • Quarterly results put Other Gross PP&E Adjustments at $37.4 million for Q4 2025, up 2.26% from a year ago — trailing twelve months through Dec 2025 was $37.4 million (up 2.26% YoY), and the annual figure for FY2025 was $37.4 million, up 2.26%.
  • Other Gross PP&E Adjustments for Q4 2025 was $37.4 million at Tonix Pharmaceuticals Holding, down from $47.7 million in the prior quarter.
  • Over the last five years, Other Gross PP&E Adjustments for TNXP hit a ceiling of $98.6 million in Q1 2024 and a floor of $36.6 million in Q4 2024.
  • Median Other Gross PP&E Adjustments over the past 3 years was $47.4 million (2025), compared with a mean of $65.5 million.
  • Biggest five-year swings in Other Gross PP&E Adjustments: crashed 58.53% in 2024 and later increased 4.4% in 2025.
  • Tonix Pharmaceuticals Holding's Other Gross PP&E Adjustments stood at $88.3 million in 2023, then crashed by 58.53% to $36.6 million in 2024, then rose by 2.26% to $37.4 million in 2025.
  • The last three reported values for Other Gross PP&E Adjustments were $37.4 million (Q4 2025), $47.7 million (Q3 2025), and $47.0 million (Q2 2025) per Business Quant data.